A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function
- DAPA-CKD Trial Committees and Investigators
- University Medical Center Groningen
- George Institute for Global Health
- University Health Network University of Toronto
- AstraZeneca R&D
- Stanford University School of Medicine
- Vanderbilt University Medical Center
- University of Utah Health Sciences
- University of Missouri-Kansas City
- University of Glasgow
- The National Medical Science and Nutrition Institute Salvador Zubiran
- Steno Diabetes Center Copenhagen
- University of Copenhagen
- University of Texas Southwestern Medical Center
- University College London
Research output: Contribution to journal › Article › peer-review
85
Scopus
citations